Novo Nordisk sheds billions in value on obesity data - Pharmaphorum
Novo Nordisk's CagriSema, an obesity therapy, showed a 20.4% weight reduction in REDEFINE 1 study, falling short of the expected 25%. Despite data suggesting a 22.7% reduction assuming full adherence, shares fell 20.7% due to concerns over side effects and performance compared to Eli Lilly's Zepbound. Future trials and regulatory filings for CagriSema are anticipated.
Highlighted Terms
Related News
Novo Nordisk sheds billions in value on obesity data - Pharmaphorum
Novo Nordisk's CagriSema, an obesity therapy, showed a 20.4% weight reduction in REDEFINE 1 study, falling short of the expected 25%. Despite data suggesting a 22.7% reduction assuming full adherence, shares fell 20.7% due to concerns over side effects and performance compared to Eli Lilly's Zepbound. Future trials and regulatory filings for CagriSema are anticipated.